Juan C Sarmiento-Monroy
Juan C. is a Rheumatologist and clinical research fellow at the Hospital Clinic of Barcelona. His main research interests include the validation of biomarkers in RA-ILD and the development of digital tools for patients with SLE. Juan C. is a member of the EMEUNET Newsletter Sub-Committee.
| Oral 0128 | Thursday, 12 June 2025 11:00 – 11:10 CEST Crystal related disorders. Oral Abstract Presentations Author: M. Andrés (Spain) Title: A proteomic analysis of subclinical synovial inflammation associated with monosodium urate crystal deposition.  This study found that subclinical inflammation associated with monosodium urate (MSU) crystal deposition in hyperuricemic patients involves elevated synovial fluid leukocyte counts and a distinctive local inflammatory proteomic profile, suggesting the process is largely confined to the joint. |
| Oral 0299 | Friday, 13 June 2025 10:30 – 10:40 CEST Clinical Poster Tours: Gout treatment in 2024 Author: Keenan, R (USA) Title: Genakumab reduces the risk of acute gout flares during initiation of urate-lowering therapy: A phase 2, randomized, open-label, multi-center, active-controlled clinical trial This 12-week, open-label, Phase 2 trial investigated the efficacy and safety of genakumab (100mg or 200mg single SC injection) versus daily oral colchicine for preventing gout flares in 162 Chinese adult males initiating ULT. Genakumab significantly reduced the average number of flares (1.8% in 100mg group, 0% in 200mg group) compared to colchicine (21.8% of patients experienced flares), with a similar safety profile. No serious adverse events or deaths occurred, and immunogenicity was low. This supports genakumab as an effective and well-tolerated prophylaxis against gout flares during ULT initiation. |
| Oral 0300| Friday, 13 June 2025 10:40 – 10:50 CEST Crystal related disorders. Oral Abstract Presentations Author: R. Keenan (USA) Title: Safety and Tolerability of Pozdeutinurad (AR882) Treatment following Long-term Dosing in Patients with Chronic Gouty Arthritis and Subcutaneous Tophi This 18-month open-label Phase 2 study investigated the long-term safety and tolerability of pozdeutinurad alone or with allopurinol (ALLO) in 42 patients with tophaceous gout. Most adverse events were mild to moderate and decreased over time, with gout flares being the most frequent. No clinically significant increases in serum creatinine or liver function abnormalities were observed with pozdeutinurad. Pozdeutinurad, both alone and combined with ALLO, was well-tolerated and more effective than ALLO alone, supporting its safety for gout treatment, even in cases with significant crystal deposition. |
| Oral 0304 | Friday, 13 June 2025 11:20 – 11:30 CEST •Crystal related disorders. Oral Abstract Presentations Author: D. Cirillo (Italy) Title: An OMERACT study for the development of an algorithm for Automatic Identification of Calcium Pyrophosphate Deposition by ultrasound: The CrystaL Artificial Intelligence Monitoring (CLAIM) study This OMERACT initiative developed an AI tool to identify and score calcium pyrophosphate deposition (CPPD) in knee menisci using ultrasound. While the initial model showed an overall accuracy of 0.69, its performance is currently insufficient for clinical application due to the small and unbalanced dataset. Future work will focus on expanding and balancing the dataset for improved accuracy. |
| Poster 1266 | Saturday, 14 June 2025 10:15 – 11:45 CEST Poster View Presentations Author: C. Moriot (France) Title: Factors associated with efficacy and safety of Anakinra for the treatment of acute crystals related arthritis. This retrospective study of 293 patients with acute crystal-related diseases (CRD) found anakinra highly effective (92.7% flare resolution). However, diabetes and longer CRD duration were linked to treatment failure. While generally safe, 5.7% developed infections, with female sex and higher baseline CRP levels identified as independent risk factors. |